Interstitial Lung Disease (ILD)
- Bridging Specialties: ILD Clinician Toolkit
- Pulmonary Fibrosis Foundation Educational Resources
- Nintedanib Prescribing Information
- Pirfenidone Prescribing Information
- Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
- Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Non-Cystic Fibrosis Bronchiectasis (NCFB)
- European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis
- Non-Cystic Fibrosis Bronchiectasis in Adults: A Review
- Bronchiectasis Management in Adults: State of the Art and Future Directions
- Diagnosis and Management of Non-Cystic Fibrosis Bronchiectasis
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
- Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
- Cathepsin C (DPP-1) Inhibition In Adults With Bronchiectasis: AIRLEAF, A Phase 2 Study Evaluating BI 1291583
- Effects of the DPP-1 Inhibitor HSK31858 in Adults With Bronchiectasis in China (SAVE-BE): A Phase 2 Study
Non-Tuberculous Mycobacteria
- Learn about NTM Lung Disease
- “INSIGHT” A Patient’s Perspective on NTM
- CDC Clinician Resources on NTM Infection
- NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources
Pulmonary Hypertension
- Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcome
- Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
- Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension
- Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study
- Pulmonary Fibrosis Foundation: PH-ILD for Patients
- Pulmonary Fibrosis Foundation: PH-ILD for Healthcare providers
- Pulmonary Hypertension Association: Patient Resources
- PAH Risk Score Calculators
- Clinical application of risk assessment in PAH: Expert center APRN recommendations
- American Lung Association PAH Patient Resources
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
